Genomic Characterization of Metastatic Castration Resistant Prostate Cancer
101 metastatic castration-resistant prostate cancers with whole genome and RNA sequencing from metastatic biopsies - every case stage IV with documented progression, and no usable vital status.
Can it answer your research question?
3 of 6 supportedOverall survival
Not supportedVital status is recorded for every case and informative for none; the cohort does carry recurrence-free interval and progression-free interval.API
Progression or recurrence
SupportedA time to event is derivable: recurrence-free interval, progression-free interval;
progression_or_recurrenceis informative for 100% of cases.APITreatment response
Limiteddisease_responseis populated for 100% of cases.APIWhich drug was given
Not supportedtherapeutic_agentsis recorded for no case in the harmonized records.APIStage-adjusted modelling
Supportedajcc_pathologic_stageis informative for 100% of cases.APIAnalysis by race or ethnicity
SupportedRace is informative for 94% of cases.API
At a glance
Every percentage is the repository’s own record of what is filled inSubjectCALC
As filed by the repository
Who is in the cohortAPI
- Sex101 male
- Race86 white · 5 black or african american · 4 asian · 6 unknown
- Ethnicity94 not hispanic or latino · 7 unknown
- Vital status101 unknown
Age at diagnosis
What was measured, and on how many
- Bulk RNA sequencing99 of 101 · 98%
- Whole genome sequencing101 of 101 · 100%
- Copy Number Variation101 of 101 · 100%
- Somatic Structural Variation101 of 101 · 100%
How complete all 29 clinical fields are - 11 informative for at least 80% of cases
Outcome
Follow-up
Treatment
Diagnosis
Demographics
Access
Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required
- Open components
- 200 open-access files
- Controlled components
- 1,700 controlled-access files
- Typical turnaround
- days to a few weeks after signing official approval
- License
- NIH Genomic Data Sharing Policy terms
- Citation requirement
- Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.
What it is good for
Written and checked by a reviewer, not generated from metadata.
1. What distinguishes the genome of metastatic castration-resistant prostate cancer from primary prostate cancer?
Needs another datasetn ≈ 101HUMANWhole genome sequencing on all 101 metastatic biopsies pairs naturally with TCGA-PRAD's 500 primary tumors in the same repository under the same harmonization. The contrast is the cohort's clearest use and does not depend on any outcome field.
Statistical note: The two cohorts differ in sequencing strategy and processing era as well as in disease state, so treat platform as a confounder rather than assuming harmonization removed it.
NeedsWhole genome sequencingCopy numberStructural variants2. Which transcriptional programs mark androgen receptor pathway independence and neuroendocrine transdifferentiation in treatment-resistant disease?
Needs approved accessn ≈ 99HUMANRNA sequencing on 99 metastatic biopsies is the right substrate for AR-signaling and neuroendocrine scoring, and metastatic tissue is where these phenotypes actually occur.
Statistical note: Biopsy site varies across the cohort and contributes substantially to expression variance; include site as a covariate or stratify.
NeedsBulk RNA sequencing3. How do structural variants and genome rearrangement patterns differ between metastatic sites?
Needs approved accessn ≈ 101HUMANStructural variant calls exist for all 101 cases from whole genome rather than exome data, which is what makes rearrangement analysis credible here.
NeedsStructural variantsWhole genome sequencing4. Can expression or genomic features predict which metastatic biopsies come from patients with the most aggressive disease trajectory?
Needs another datasetn ≈ 101HUMANThis is the question most people want the cohort for, and it is the one the harmonized records cannot support. It is listed here to be explicit that it requires outcome data obtained separately.
Statistical note: Not answerable from the GDC records alone. Vital status is "unknown" for every case; outcomes must come from the marker publication's supplement or a dbGaP phenotype file.
NeedsBulk RNA sequencingWhole genome sequencingOutcome data
What it cannot tell you
Written by a reviewer against the source, not inferred from what is missing.
Vital status is populated for all 101 cases and informative for none - every value is "unknown". No overall survival endpoint exists in the harmonized records, despite a follow-up time being derivable for 87 of 101 cases with a median of 95 months.
Affects: Overall survival; Prognostic modeling; Outcome-anchored biomarker discovery
Mitigation: Outcome data are analyzed in the PNAS marker paper. Obtain them from its supplementary material or through dbGaP before planning any survival work.
No treatment field is populated: treatment type, therapeutic agents, treatment outcome and line of therapy are all empty. These are castration-resistant patients, so every one has had prior androgen deprivation and most will have had further systemic therapy, but which therapy and in what order is not recorded here.
Affects: Treatment-response analysis; Resistance mechanism attribution; Line-of-therapy stratification
Mitigation: Do not attribute molecular features to specific treatments using these records. The absence of treatment annotation in a treatment-defined cohort is the single most important thing to know before selecting it.
101 cases limits subgroup analysis sharply. Any stratification by biopsy site, molecular subtype or genomic alteration leaves groups in the low tens.
Affects: Subgroup comparisons; Rare-variant association
Mitigation: Pre-specify a small number of hypotheses; treat subgroup results as exploratory.
86 of 101 cases are recorded as white and 5 as Black or African American, in a disease with pronounced incidence and mortality disparities affecting Black men.
Affects: Disparities research; Ancestry-stratified analysis
Mitigation: Do not use this cohort to characterise metastatic prostate cancer biology in Black patients; five cases cannot support it.
1,700 of 1,900 files are controlled access.
Affects: Any sequence-level analysis
Mitigation: Budget several weeks for the dbGaP request.
Not appropriate for
- Survival analysis or prognostic biomarker discovery from the GDC records. - Vital status is uninformative for all 101 cases.HUMAN
- Attributing resistance mechanisms to particular drugs. - No treatment is recorded for any case, so drug attribution would be invented rather than observed.HUMAN
- Studying prostate cancer disparities. - Five Black patients cannot support a disparities analysis.HUMAN
Who has used it
Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.
What articles did with it
- Cited the paper1,206
- Mentioned the dataset1
- Accession found in text29
- Declared using it24
- Analyzed the data27
Against comparable datasets
- Analyzed it27
- Expected~10
- Reuse is within the expected range for comparable datasets (index +1.38).
Original publication
Articles that analyzed the data
Community examples
Share your exampleAnalyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.
Which classes of analysis do this cohort's clinical records actually support, and which are ruled out before I request access?
Audit whether this dataset can answer your question
- A GDC project identifier
- Network access to api.gdc.cancer.gov
- Per-field coverage table separating populated from informative values
- Assay coverage as a percentage of the cohort
- A yes/no verdict for six common analysis classes
- A chart contrasting populated with informative coverage, field by field
Steps
- Fetch project summary and per-assay case counts
- Request facet counts for the clinical fields that gate common analyses
- Separate absent fields from fields populated with non-answers
- Flag one-to-many fields where per-case percentages cannot be inferred
- Retrieve case-level fields and test whether a survival endpoint is derivable
- Print a verdict for each analysis class
Start here
Starter code generated from this record’s own identifiers, then the access steps.
Get the data in code
GDC: list open files and download thempython
import json, requests
PROJECT = "WCDT-MCRPC"
filters = {"op": "and", "content": [
{"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
{"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
"fields": "file_id,file_name,data_category,data_type,file_size",
"size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")
# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txtGDC: clinical table for every casepython
import json, requests
filters = {"op": "in", "content": {"field": "project.project_id", "value": ["WCDT-MCRPC"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
"fields": ",".join([
"submitter_id", "demographic.vital_status", "demographic.days_to_death",
"diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
"diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("WCDT-MCRPC_clinical.tsv", "w").write(tsv)This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-wcdt-mcrpc.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'Access steps
- Read the PNAS marker paper for the clinical annotationFor people
It carries the outcome and treatment context that the harmonized records lack. Decide from it whether your question is viable.
https://pubmed.ncbi.nlm.nih.gov/31061129/ - Scope with the 200 open-access filesFor peoplehttps://portal.gdc.cancer.gov/projects/WCDT-MCRPC
- Submit a dbGaP data access requestFor peoplehttps://gdc.cancer.gov/access-data/obtaining-access-controlled-data
- Query the project from code, with no credentialsFor agents
The file index is public even where files are not, so an agent can size the cohort before anyone requests access.
https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/curl -s 'https://api.gdc.cancer.gov/files' --get \ --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["WCDT-MCRPC"]}}' \ --data-urlencode 'fields=file_id,file_name,data_type' \ --data-urlencode 'size=10000' --data-urlencode 'format=TSV' - Pass the token when the agent needs controlled filesFor agents
Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.
https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
Provenance
All of it, and more, is in this record’s JSON.
Identifiers
- GDC projectWCDT-MCRPCAPI
- GDC programAPI
- dbGaP studyphs001648API
Versions and verification
- Released
- 1 Jan 2019
- Metadata retrieved
- 18 Sept 2026
- Review status
- Project-curatedCD2S project curation on 18 Sept 2026
- Data generation funding
- Funded data generation
- The PNAS marker paper reports clinical outcomes for this cohort, but vital status is "unknown" for all 101 cases in the GDC harmonized records. Confirm whether outcome data are obtainable from the supplementary material or only under dbGaP terms.
Funding
Funded data generation
- P50CA092629Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate CancerBrett Stewart Carver, Yu ChenAPI2
- P30CA008748Cancer Center AdministrationALEX MACDONALD, SELWYN M VICKERSAPI2
- P50CA186786Michigan Prostate SPORE 2025-2030ARUL M CHINNAIYAN, Ganesh S PalapattuAPI2
- P50CA090381Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer ProgressMassimo Loda, Steven P. BalkAPI2
- U54CA224079Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapyYu Chen, CHARLES L. SAWYERSAPI2
- P50CA211024Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate CancerHimisha Beltran, David S. RickmanAPI2
- P50CA097186Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)Martin Edwin Gleave, RUTH D ETZIONIAPI2
- R01CA155169Understanding Resistance to Next Generation AntiandrogensCHARLES L. SAWYERSAPI
- R01CA125612Towards Understanding Prostate Cancer HeterogeneityMARK A. RUBINAPI
Funded reuse of these data
- R35CA197566Mechanisms governing metastatic dormancy and reactivationFILIPPO G GIANCOTTIAPI
- R00CA194289MDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration ResistanceGuocan WangAPI
- T32CA108462Molecular and Cellular Mechanisms in CancerANDREI GOGA, ZENA WERBAPI
- R01CA251245Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain InhibitionJoshi James AlumkalAPI
- R01CA230516DNA repair alterations in metastatic prostate cancer: functional and therapeutic implicationsAlan Ashworth, Felix Yi-Chung FengAPI
- R01CA227025Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic StrategiesFelix Yi-Chung Feng, Nupam P MahajanAPI
- R01CA251555Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesMATTHEW L FREEDMAN, Bogdan PasaniucAPI
- R01CA193910Defining the epigenetic landscape in human prostate cancerMYLES A BROWN, MATTHEW L FREEDMANAPI
- R00CA135592Androgen Receptor Regulation by PhosphorylationShaoyong ChenAPI
- K99CA135592Androgen Receptor Regulation by PhosphorylationShaoyong ChenAPI
Funded infrastructure or harmonization
- P50CA140388Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPOREChristopher J. Logothetis, Timothy Charles ThompsonAPI
- P30CA016672The University of Texas MD Anderson Cancer Center Support Grant (CCSG)PETER W PISTERS, Vicki HuffAPI
- P01CA094060TGF&, PI3K and HER2 Pathways in Breast Cancer MetastasisJOAN MASSAGUE, SCOTT W. LOWEAPI
- P30CA093373Integrated Cancer Biology ProgramWolf-Dietrich Heyer, KIT S LAMAPI
- P30CA082103Leadership, Planning and EvaluationAlan Ashworth, Charles Scott CraikAPI
- U54CA156732The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities ResearchGregory Alan Abel, KASISOMAYAJULA VISWANATHAPI
- P01CA163227Androgen Receptor Action in Castration Resistant Prostate CancerSteven P. Balk, PETER S NELSONAPI
- U01CA268933Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancerMelissa Abel, Mehmet TonerAPI
- U01CA224044Patient-Derived Models of Prostate Cancer for Personalized MedicineYu Chen, PHILLIP ANDREW FUTREALAPI
- P30CA015704Prostate CancerPETER S NELSON, Marion Shonn DorerAPI